(NASDAQ: CLRB) Cellectar Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.9%.
Cellectar Biosciences's earnings in 2025 is -$29,072,032.On average, 2 Wall Street analysts forecast CLRB's earnings for 2025 to be -$34,569,793, with the lowest CLRB earnings forecast at -$37,314,948, and the highest CLRB earnings forecast at -$31,824,639. On average, 3 Wall Street analysts forecast CLRB's earnings for 2026 to be -$21,067,464, with the lowest CLRB earnings forecast at -$29,558,290, and the highest CLRB earnings forecast at -$10,852,936.
In 2027, CLRB is forecast to generate -$26,781,216 in earnings, with the lowest earnings forecast at -$31,665,037 and the highest earnings forecast at -$21,897,394.